Delving into the Latest Updates on Recombinant anti-EGFR chimeric antibody(Shanghai Zhangjiang Biotechnology Co Ltd) with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms-

Target

EGFR

Action

antagonists

Mechanism

EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Advanced cancer

Originator Organization

Shanghai Zhangjiang Biotechnology Co. Ltd.

Active Organization-

Inactive Organization

Shanghai Zhangjiang Biotechnology Co. Ltd.

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

To observe the safety of recombinant anti-EGFR human-mouse chimeric monoclonal antibody in humans, determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and pharmacokinetic characteristics of the drug after single and multiple intravenous administration in humans, and recommend a safe dose for Phase II clinical studies.

Start Date-

Sponsor / Collaborator

Shanghai Zhangjiang Biotechnology Co. Ltd.

100 Clinical Results associated with Recombinant anti-EGFR chimeric antibody(Shanghai Zhangjiang Biotechnology Co Ltd)

Login to view more data

100 Translational Medicine associated with Recombinant anti-EGFR chimeric antibody(Shanghai Zhangjiang Biotechnology Co Ltd)

Login to view more data

100 Patents (Medical) associated with Recombinant anti-EGFR chimeric antibody(Shanghai Zhangjiang Biotechnology Co Ltd)

Login to view more data

100 Deals associated with Recombinant anti-EGFR chimeric antibody(Shanghai Zhangjiang Biotechnology Co Ltd)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced cancer	Phase 1	China	Shanghai Zhangjiang Biotechnology Co. Ltd.	23 Oct 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data